Personalized Medicine and Access to Therapeutic Innovations Unit
Since 2010, the CGFL has housed one of the 16 CLIP2-certified centers, for innovative and personalized care.
Together, let’s overcome cancer.
The CLIP2
Since 2010, the CGFL in Dijon has housed one of the 16 INCa CLIP² Labeled Centers in France.
Renewed for 2024-2029, this label results from a fruitful collaboration between the CGFL and the Dijon and Besançon University Hospitals, thus strengthening its regional roots.
CLIP² BFC focuses on several types of cancer, including digestive, pulmonary, gynecological, breast, ENT, melanoma and lymphoma.
Thanks to modern infrastructure and expertise in research and innovation, CLIP² BFC offers innovative and personalized care, benefiting patients in the inter-region and beyond.
With 20 places, the Personalized Medicine and Access to Therapeutic Innovations Unit (UMPI) is a unique unit in France, allowing the centralized management of all patients treated in a clinical trial. This unit, with a dedicated medical and paramedical team, will allow all patients to benefit from therapeutic innovation with the highest quality standards.
The development of clinical research at the CGFL is therefore based on 5 main axes:
Axis 1
Strengthening phase I/II clinical trials
This initiative will result in increased involvement in national and international trials, expanding the scope of clinical research. Strengthened collaboration between the CGFL, Dijon University Hospital, and Besançon sites will optimize resources and improve access to trials for patients in the region. CLIP² BFC will also strengthen its partnerships with industrial and academic sponsors, fostering innovation and access to new therapies. This collaborative and multifaceted approach aims to position CLIP² BFC as a major player in early clinical research in oncology.
Axis 2
Development of early studies with internal promotion
CLIP² BFC will focus on innovative projects specific to each site. The emphasis is on immunotherapy and the targeting of digestive, lung, gynecological, breast, ENT cancers, melanoma, and lymphoma. This strategy is based on strengthened collaborations with the INSERM 1231 (Dijon) and INSERM 1098 research units, thus promoting the rapid transfer of fundamental discoveries to the clinic. In parallel, an ambitious program to identify new biomarkers using liquid biopsy is also being launched, including the analysis of circulating tumor DNA, T cells, and extracellular vesicles, aimed at improving early diagnosis and personalized patient monitoring.
Axis 3
Development of new therapeutic strategies
At the heart of this initiative is the integration of three promising approaches: the UCPVax program, focused on therapeutic vaccination, cell therapy with a particular emphasis on CAR-T cells, and the advanced use of radiotherapy through LINAC-MRI, notably in the Immunosbrt and Nanocosmos trials. In parallel, in-depth studies are being conducted on the reprogramming of the tumor microenvironment, aimed at optimizing the efficacy of treatments. Particular attention is also being paid to research on the mechanisms of resistance to immunotherapy, with the aim of developing strategies to overcome these obstacles and improve clinical outcomes.
Axis 4
Precision medicine and optimized clinical trials
The development of precision medicine relies on high-throughput sequencing to establish precise molecular profiles. This approach enables optimal patient selection for clinical trials and personalized treatment. Programs such as EXOMA and SELECTO will strengthen regional molecular screening, while ONCOBOARD, connected to the OncoClic application, will facilitate collaboration between experts via remote expertise. At the same time, improving the quality of clinical trials will rely on OWLIA, an artificial intelligence platform. It optimizes data management, standardizes procedures, and provides real-time monitoring. This innovation aims to strengthen the reliability of results, accelerate research processes, and facilitate informed decision-making.
Axis 5
Patient involvement and enhanced training in clinical research
CLIP² BFC is committed to actively involving patients and associations in clinical research. Early trial protocols will be reviewed by the Biomedical Research Committee of the Ligue contre le Cancer and presented to the CRUQ, thus integrating patient perspectives. At the same time, CLIP² will strengthen clinical research training for future healthcare professionals. Specific courses will be offered to CGFL staff, addressing the ethics and organization of clinical trials. This initiative will extend to the IFSI and the EPHE translational research programs, raising awareness among a wide range of professionals about the importance of clinical trials.
Innovation and research unit in immunotherapy and early phase (Georges-François Leclerc Center, DIJON)
Coordinator (adults):
Professor François Ghiringhelli
CLIP² project manager:
Dr Jessica Gobbo
Partner sites
Department of Clinical Hematology (François Mitterrand Hospital, Dijon-Bourgogne University Hospital, DIJON)
Referring Physician:
Professor Cédric Rossi
Department of Medical Oncology – Cancer Immunotherapy (Jean-Minjoz Hospital, Besançon University Hospital, BESANCON)
Referring Physician:
Professor Christophe BORG
Hematology Department (Jean-Minjoz Hospital, Besançon University Hospital, BESANCON)
Referring doctor:
Prof. Eric DECONNINCK